The biologic drug interferon-alpha can benefit patients with blood cancers called myeloproliferative neoplasms by forcing mutant blood stem cells to become shorter-lived white blood cells.
Metabotropic glutamate receptors interact in varied ways with their principal regulatory proteins, according to Weill Cornell Medicine investigators. The findings could inform treatments for epilepsy, depression and anxiety disorders.
Cornell and global leaders will come together at Climate Week NYC Sept. 20-27 to discuss some of the world’s most pressing sustainability challenges, including harnessing AI’s power while mitigating its negative impacts.
A team of Weill Cornell Medicine investigators has developed a computer model that will help scientists more efficiently develop protein-destroying therapies, a newer type of treatment that is particularly promising for cancer.